Aqua Medical

Executive Summary

Aqua Medical is a US-based medical device company pioneering a novel vapor ablation platform designed for through-the-endoscope treatment of metabolic diseases. Its lead application targets type 2 diabetes by performing a 30-minute outpatient procedure that ablates the duodenal mucosa, aiming to improve glycemic control. This non-pharmacologic intervention has the potential to alter the natural progression of diabetes, offering an alternative for patients who cannot achieve adequate control with existing therapies. Founded in 2018 and headquartered in Irvine, California, the company is privately held and has not disclosed financing details, but its technology addresses a significant unmet need in the metabolic disease space. The platform leverages endoscopic delivery of vapor to precisely ablate targeted tissue, positioning it as a minimally invasive alternative to more radical surgical interventions. If successful, Aqua Medical could capture a substantial share of the diabetes treatment market, which is projected to exceed $50 billion annually. However, the company remains in early stages of development, with no disclosed clinical data or regulatory milestones to date. Key risks include proving safety and efficacy in clinical trials, securing regulatory approval from the FDA, and competing with established pharmacological and device-based therapies. The company's ability to navigate these challenges will determine its long-term viability and impact.

Upcoming Catalysts (preview)

• H2 2026Initiation of First-in-Human Clinical Trial70% success
• Q1 2027FDA Investigational Device Exemption (IDE) Approval60% success
• 2027Strategic Partnership with a Major Medical Device Company50% success